

CRR
JOURNAL
OF CARDIORESPIRATORY RESEARCH

ISSN 2181-0974
DOI 10.26739/2181-0974
Impact Factor SJIF 2022: 5.937

Journal of

**CARDIORESPIRATORY
RESEARCH**



Volume 7, Issue 2/3

2026

МИНИСТЕРСТВО ЗДРАВООХРАНЕНИЯ
РЕСПУБЛИКИ УЗБЕКИСТАН

Журнал кардиореспираторных исследований

JOURNAL OF CARDIORESPIRATORY RESEARCH

Главный редактор: Э.Н.ТАШКЕНБАЕВА

Учредитель:

Самаркандский государственный
медицинский университет

Tadqiqot.uz

Ежеквартальный
научно–практический
журнал

ISSN: 2181-0974
DOI: 10.26739/2181-0974



№ 2/3
2026

Главный редактор:

Ташкенбаева Элеонора Негматовна

доктор медицинских наук, профессор, заведующая кафедрой внутренних болезней и кардиологии №2 Самаркандского Государственного медицинского университета, председатель Ассоциации терапевтов Самаркандской области.
<https://orcid.org/0000-0001-5705-4972>

Заместитель главного редактора:

Хайбулина Зарина Руслановна

*доктор медицинских наук, руководитель отдела биохимии с группой микробиологии
ГУ «РСНПМЦХ им. акад. В. Вахидова» <https://orcid.org/0000-0002-9942-2910>*

ЧЛЕНЫ РЕДАКЦИОННОЙ КОЛЛЕГИИ:

Аляви Анис Лютфуллаевич

академик АН РУз, доктор медицинских наук, профессор, Председатель Ассоциации Терапевтов Узбекистана, Советник директора Республиканского специализированного научно-практического центра терапии и медицинской реабилитации (Ташкент)
<https://orcid.org/0000-0002-0933-4993>

Бокерия Лео Антонович

академик РАН, доктор медицинских наук, профессор, Президент научного центра сердечно-сосудистой хирургии им. А.Н. Бакулева (Москва), <https://orcid.org/0000-0002-6180-2619>

Курбанов Равшанбек Давлетович

академик АН РУз, доктор медицинских наук, профессор, Советник директора Республиканского специализированного научно-практического медицинского центра кардиологии (Ташкент), <https://orcid.org/0000-0001-7309-2071>

Шкляев Алексей Евгеньевич

д.м.н., профессор, ректор Федерального государственного бюджетного образовательного учреждения высшего образования «Ижевская государственная медицинская академия» Министерства здравоохранения Российской Федерации

Michał Tendera

профессор кафедры кардиологии Верхнесилезского кардиологического центра, Силезский медицинский университет в Катовице, Польша (Польша)
<https://orcid.org/0000-0002-0812-6113>

Покушалов Евгений Анатольевич

доктор медицинских наук, профессор, заместитель генерального директора по науке и развитию сети клиник «Центр новых медицинских технологий» (ЦНМТ), (Новосибирск), <https://orcid.org/0000-0002-2560-5167>

Зуфаров Миржамол Мирумарович

доктор медицинских наук, профессор, руководитель отдела ГУ «РСНПМЦХ им. акад. В. Вахидова» <https://orcid.org/0000-0003-4822-3193>

Акилов Хабибулла Атауллаевич

доктор медицинских наук, профессор, Директор Центра развития профессиональной квалификации медицинских работников (Ташкент)

Насирова Зарина Акбаровна

DSc, доцент кафедры внутренних болезней и кардиологии №2 Самаркандского Государственного Медицинского университета (ответственный секретарь) ORCID: 0000-0002-8722-0393 (ответственный секретарь)

Ризаев Жасур Алимджанович

доктор медицинских наук, профессор, Ректор Самаркандского государственного медицинского университета, <https://orcid.org/0000-0001-5468-9403>

Зиядуллаев Шухрат Худойбердиевич

доктор медицинских наук, профессор, первый заместитель директора по академической деятельности Самаркандского филиала Международного Университета Кимё в Ташкенте
<https://orcid.org/0000-0002-9309-3933>

Джан Ковак

Профессор, председатель Совета Европейского общества кардиологов по инсульту, руководитель специализированной кардиологии, заведующий отделением кардиологии, кардио- и торакальной хирургии, консультант-кардиолог, больница Гленфилд, Лестер (Великобритания)

Сергио Бернардини

Профессор клинической биохимии и клинической молекулярной биологии, главный врач отдела лабораторной медицины, больница Университета Тор Вергата (Рим, Италия)

Ливерко Ирина Владимировна

доктор медицинских наук, профессор, заместитель директора по науке Республиканского специализированного научно-практического медицинского центра фтизиатрии и пульмонологии Республики Узбекистан (Ташкент)
<https://orcid.org/0000-0003-0059-9183>

Цурко Владимир Викторович

доктор медицинских наук, профессор Первого Московского государственного медицинского университета им. И.М. Сеченова (Москва)
<https://orcid.org/0000-0001-8040-3704>

Тригулова Ранса Хусановна

Доктор медицинских наук, руководитель лаборатории превентивной кардиологии, ведущий научный сотрудник лаборатории ИБС и атеросклероза. Республиканский специализированный научно-практический медицинский центр кардиологии (Ташкент)
ORCID- 0000-0003-4339-0670

Тураев Феруз Фатхуллаевич

доктор медицинских наук, Директор Республиканского специализированного научно-практического медицинского центра эндокринологии имени академика Ю.Г. Туракулова

Bosh muharrir:

Tashkenbayeva Eleonora Negmatovna

tibbiyot fanlari doktori, professor, Samarqand davlat tibbiyot universiteti 2-sonli ichki kasalliklar va kardiologiya kafedrasini mudiri, Samarqand viloyati vrachlar uyushmasi raisi
<https://orsid.org/0000-0001-5705-4972>

Bosh muharrir o'rinbosari:

Xaibulina Zarina Ruslanovna

tibbiyot fanlari doktori, "akad V. Vohidov nomidagi RIJM davlat institutining mikrobiologiya guruhi bilan biokimyo kafedrasini mudiri" <https://orcid.org/0000-0002-9942-2910>

TAHRIRIYAT A'ZOLARI:

Alyavi Anis Lyutfullayevich

O'zbekiston Respublikasi Fanlar akademiyasining akademigi, tibbiyot fanlari doktori, professor, O'zbekiston Terapevtlar uyushmasi raisi, Respublika ixtisoslashtirilgan ilmiy va amaliy tibbiy terapiya markazi va tibbiy reabilitatsiya direktori maslahatchisi (Toshkent), <https://orcid.org/0000-0002-0933-4993>

Bockeria Leo Antonovich

Rossiya fanlar akademiyasining akademigi, tibbiyot fanlari doktori, professor, A.N. Bakuleva nomidagi yurak-qon tomir jarrohligi ilmiy markazi prezidenti (Moskva)
<https://orcid.org/0000-0002-6180-2619>

Kurbanov Ravshanbek Davlatovich

O'zbekiston Respublikasi Fanlar akademiyasining akademigi, tibbiyot fanlari doktori, professor, Respublika ixtisoslashtirilgan kardiologiya ilmiy-amaliy tibbiyot markazining direktor maslahatchisi (Toshkent)
<https://orcid.org/0000-0001-7309-2071>

Shklyayev Aleksey Evgenievich

Tibbiyot fanlari doktori, professor, Rossiya Federatsiyasi Sog'liqni saqlash vazirligining "Izhevsk davlat tibbiyot akademiyasi" Federal davlat byudjeti oliy ta'lim muassasasi rektori

Mixal Tendera

Katovitsadagi Sileziya Tibbiyot Universiteti, Yuqori Sileziya Kardiologiya Markazi kardiologiya kafedrasini professori (Polsha)
<https://orcid.org/0000-0002-0812-6113>

Pokushalov Evgeniy Anatolevich

tibbiyot fanlari doktori, professor, "Yangi tibbiy texnologiyalar markazi" (YTTM) klinik tarmog'ining ilmiy ishlar va rivojlanish bo'yicha bosh direktorining o'rinbosari (Novosibirsk) <https://orcid.org/0000-0002-2560-5167>

Zufarov Mirjamol Mirumarovich

tibbiyot fanlari doktori, professor, "akad V. Vohidov nomidagi RIJM davlat muassasasi" bo'limi boshlig'i"
<https://orcid.org/0000-0003-4822-3193>

Akilov Xabibulla Ataulayevich

tibbiyot fanlari doktori, professor, Tibbiyot xodimlarining kasbiy malakasini oshirish markazi direktori (Toshkent)

Nasirova Zarina Akbarovna

Samarqand davlat tibbiyot universiteti 2-sonli ichki kasalliklar va kardiologiya kafedrasini dotsenti, DSc (mas'ul kotib) ORCID: 0000-0002-8722-0393 (*mas'ul kotib*)

Rizayev Jasur Alimjanovich

tibbiyot fanlari doktori, professor, Samarqand davlat tibbiyot universiteti rektori
<https://orcid.org/0000-0001-5468-9403>

Ziyadullayev Shuxrat Xudoyberdiyevich

tibbiyot fanlari doktori, professor, Toshkent shahridagi Kimyo xalqaro universitetining Samarqand filiali direktorining akademik faoliyat bo'yicha birinchi o'rinbosari (Toshkent)
<https://orcid.org/0000-0002-9309-3933>

Jan Kovak

Yevropa kardiologiya jamiyati insult kengashi raisi, 2017 yildan buyon ixtisoslashtirilgan kardiologiya kafedrasini rahbari, kardiologiya, yurak va torakal jarrohlik kafedrasini mudiri, maslahatchi kardiolog Glenfild kasalxonasi, Lester (Buyuk Britaniya)

Sergio Bernardini

Klinik biokimyo va klinik molekulyar biologiya bo'yicha professor - Laboratoriya tibbiyoti bo'limi bosh shifokori – Tor Vergata universiteti kasalxonasi (Rim-Italiya)

Liverko Irina Vladimirovna

tibbiyot fanlari doktori, professor, Respublika ixtisoslashtirilgan fiziologiya va pulmonologiya ilmiy-amaliy tibbiyot markazining ilmiy ishlar bo'yicha direktor o'rinbosari (Toshkent)
<https://orcid.org/0000-0003-0059-9183>

Surko Vladimir Viktorovich

tibbiyot fanlari doktori, professori I.M. Sechenov nomidagi Birinchi Moskva Davlat tibbiyot universiteti (Moskva)
<https://orcid.org/0000-0001-8040-3704>

Trigulova Raisa Xusainovna

Tibbiyot fanlari doktori, Profilaktik kardiologiya laboratoriyasi mudiri, YuIK va ateroskleroz laboratoriyasining yetakchi ilmiy xodimi. Respublika ixtisoslashtirilgan kardiologiya ilmiy-amaliy tibbiyot markazi (Toshkent) ORCID- 0000-0003-4339-0670

Turayev Feruz Fatxullayevich

tibbiyot fanlari doktori, akademik Y.X.To'raqulov nomidagi Respublika ixtisoslashtirilgan endokrinologiya ilmiy amaliy tibbiyot markazi direktori
<https://orcid.org/0000-0002-1321-4732>

Chief Editor:

Tashkenbaeva Eleonora Negmatovna

Doctor of Medical Sciences, professor, Head of the Department of Internal Diseases and cardiology No. 2 of the Samarkand State Medical University, Chairman of the Association of Physicians of the Samarkand Region. <https://orsid.org/0000-0001-5705-4972>

Deputy Chief Editor:

Xaibulina Zarina Ruslanovna

Doctor of Medical Sciences, Head of the Department of Biochemistry with the Microbiology Group of the State Institution "RSSC named after acad. V. Vakhidov", <https://orcid.org/0000-0002-9942-2910>

MEMBERS OF THE EDITORIAL BOARD:

Alyavi Anis Lutfullaevich

Academician of the Academy of Sciences of the Republic of Uzbekistan, Doctor of Medical Sciences, Professor, Chairman of the Association of Physicians of Uzbekistan, Advisor to the Director of the Republican Specialized Scientific - Practical Center of Therapy and Medical Rehabilitation (Tashkent) <https://orcid.org/0000-0002-0933-4993>

Bockeria Leo Antonovich

Academician of the Russian Academy of Sciences, Doctor of Medical Sciences, Professor, President of the Scientific Center for Cardiovascular Surgery named after A.N. Bakuleva (Moscow) <https://orcid.org/0000-0002-6180-2619>

Kurbanov Ravshanbek Davletovich

Academician of the Academy of Sciences of the Republic of Uzbekistan, Doctor of Medical Sciences, Professor, Advisor to the Director Republican Specialized Scientific and Practical Medical Center of Cardiology, (Tashkent) <https://orcid.org/0000-0001-7309-2071>

Shklyayev Aleksey Evgenievich

Doctor of Medical Sciences, Professor, Rector of the Federal State Budgetary Educational Institution of Higher Education "Izhevsk State Medical Academy" of the Ministry of Health of the Russian Federation

Michal Tendera

Professor of the Department of Cardiology, Upper Silesian Cardiology Center, Silesian Medical University in Katowice, Poland (Poland) <https://orcid.org/0000-0002-0812-6113>

Pokushalov Evgeny Anatolyevich

Doctor of Medical Sciences, Professor, Deputy Director General for Science and Development of the Clinic Network "Center for New Medical Technologies" (CNMT), (Novosibirsk) <https://orcid.org/0000-0002-2560-5167>

Akilov Xabibulla Ataulaevich

Doctor of Medical Sciences, Professor, Center for the development of professional qualifications of medical workers (Tashkent)

Nasyrova Zarina Akbarovna

DSc, Associate Professor of the Department of Internal Diseases and cardiology No. 2 of the Samarkand State Medical University (Executive Secretary) ORCID: 0000-0002-8722-0393 (Executive Secretary)

Rizaev Jasur Alimjanovich

Doctor of Medical Sciences, Professor, Rector of the Samarkand State Medical University <https://orcid.org/0000-0001-5468-9403>

Ziyadullaev Shuhrat Khudoyberdievich

Doctor of Medical Sciences, Professor, Deputy Director for Scientific Doctor of Medical Sciences, Professor, First Deputy Director for Academic Affairs of the Samarkand branch of Kimyo International University in Tashkent <https://orcid.org/0000-0002-9309-3933>

Jan Kovac

Professor Chairman, European Society of Cardiology Council for Stroke, Lead of Specialised Cardiology, Head of Cardiology, Cardiac and Thoracic Surgery, Consultant Cardiologist, Glenfield Hospital, Leicester (United Kingdom)

Sergio Bernardini

Full Professor in Clinical Biochemistry and Clinical Molecular Biology -Head Physician of the Laboratory Medicine Unit- University of Tor Vergata Hospital (Rome-Italy)

Liverko Irina Vladimirovna

Doctor of Medical Sciences, Professor, Deputy Director for Science of the Republican Specialized Scientific and Practical Medical Center for Phthiology and Pulmonology of the Republic of Uzbekistan (Tashkent) <https://orcid.org/0000-0003-0059-9183>

Zufarov Mirjamol Mirumarovich

Doctor of Medical Sciences, Professor, Head of the Department of the State Institution "RSNPMTSH named after acad. V. Vakhidov" <https://orcid.org/0000-0003-4822-3193>

Tsurko Vladimir Viktorovich

Doctor of Medical Sciences, professor Of Moscow State Medical University by name I.M. Sechenov (Moscow) <https://orcid.org/0000-0001-8040-3704>

Trigulova Raisa Khusainovna

Doctor of Medical Sciences, Head of the Laboratory of Preventive Cardiology, Leading Researcher of the Laboratory of IHD and Atherosclerosis. Republican Specialized Scientific and Practical Medical Center of Cardiology (Tashkent) ORCID- 0000-0003-4339-0670

Turaev Feruz Fatxullaevich

Doctor of Medical Sciences, Director of the Republican Specialized Scientific and Practical Medical Center of Endocrinology named after Academician Yu.G. Turakulova

Алимов Дониёр Анварович
доктор медицинских наук, директор
Республиканского научного центра
экстренной медицинской помощи

Абдуллаев Акбар Хатамович
доктор медицинских наук, главный
научный сотрудник Республиканского
специализированного научно-
практического центра медицинской
терапии и реабилитации
<https://orcid.org/0000-0002-1766-4458>

Агабабян Ирина Рубеновна
кандидат медицинских наук, доцент,
заведующая кафедрой терапии ФПДО,
Самаркандского Государственного
медицинского института

Алиева Нигора Рустамовна
доктор медицинских наук, заведующая
кафедрой Госпитальной педиатрии №1
с основами нетрадиционной медицины
ТашПМИ

Исмаилова Адолат Абдурахимовна
доктор медицинских наук, профессор,
заведующая лабораторией
фундаментальной иммунологии
Института иммунологии геномики
человека АН РУз

Камалов Зайнитдин Сайфутдинович
доктор медицинских наук, профессор,
заведующий лабораторией
иммунорегуляции Института
иммунологии и геномики
человека АН РУз

Каюмов Улугбек Каримович
доктор медицинских наук, профессор,
заведующий кафедрой внутренних
болезней и телемедицины Центра
развития профессиональной
квалификации медицинских работников

Хусинова Шоира Акбаровна
кандидат философских наук, доцент,
заведующая кафедрой общей практики,
семейной медицины ФПДО
Самаркандского Государственного
медицинского института

Шодиколова Гуландом Зикрияевна
д.м.н., профессор, заведующая
кафедрой внутренних болезней № 3
Самаркандского Государственного
Медицинского Института
(Самарканд)
<https://orcid.org/0000-0003-2679-1296>

Doniyorova Farangisbonu Alisher qizi
Toshkent Davlat tibbiyot universiteti
nevrologiya va xalq tabobati kafedrasida
dotsenti, DSc.
<https://orcid.org/0009-0004-4140-4797>

Alimov Doniyor Anvarovich
tibbiyot fanlari doktori, Respublika
shoshilinch tibbiy yordam ilmiy
markazi direktori (Toshkent)

Abdullayev Akbar Xatamovich
tibbiyot fanlari doktori, O'zbekiston
Respublikasi Sog'liqni saqlash
vazirligining "Respublika
ixtisoslashtirilgan terapiya va tibbiy
reabilitatsiya ilmiy-amaliy
tibbiyot markazi" davlat
muassasasi bosh ilmiy xodimi
<https://orcid.org/0000-0002-1766-4458>

Agababayan Irina Rubenovna
tibbiyot fanlari nomzodi, dotsent,
DKTF, terapiya kafedrasida mudiri,
Samarqand davlat tibbiyot instituti

Alieva Nigora Rustamovna
tibbiyot fanlari doktori, 1-sonli
gospital pediatriya kafedrasida mudiri,
ToshPТИ

Ismoilova Adolat Abduraximovna
tibbiyot fanlari doktori, professor,
O'zbekiston Respublikasi Fanlar
akademiyasining Odam genomikasi
immunologiyasi institutining
fundamental immunologiya
laboratoriyasining mudiri

Kamalov Zaynitdin Sayfutdinovich
tibbiyot fanlari doktori, professor,
O'zbekiston Respublikasi Fanlar
akademiyasining Immunologiya va
inson genomikasi institutining
Immunogenetika laboratoriyasi mudiri

Qayumov Ulug'bek Karimovich
tibbiyot fanlari doktori, professor,
Tibbiyot xodimlarining kasbiy
malakasini oshirish markazi, ichki
kasalliklar va teletibbiyot kafedrasida
mudiri (Toshkent)

Xusinova Shoira Akbarovna
tibbiyot fanlari nomzodi, dotsent,
Samarqand davlat tibbiyot instituti
DKTF Umumiy amaliyot va oilaviy
tibbiyot kafedrasida mudiri (Samarqand)

Shodiqulova Gulandom Zikriyevna
tibbiyot fanlari doktori, professor,
Samarqand davlat tibbiyot instituti 3-
ichki kasalliklar kafedrasida mudiri
(Samarqand)
<https://orcid.org/0000-0003-2679-1296>

**Дониярова Фарангисбону Алишер
кизи**
доцент кафедры неврологии и
народной медицины Ташкентского
государственного медицинского
университета, доктор медицинских
наук. <https://orcid.org/0009-0004-4140-4797>

Alimov Doniyor Anvarovich
Doctor of Medical Sciences, Director of
the Republican Scientific Center of
Emergency Medical Care

Abdullaev Akbar Xatamovich
Doctor of Medical Sciences,
Chief Researcher of the State Institution
"Republican Specialized Scientific and
Practical Medical Center for Therapy and
Medical Rehabilitation" of the Ministry of
Health of the Republic of Uzbekistan,
<https://orcid.org/0000-0002-1766-4458>

Agababayan Irina Rubenovna
PhD, Associate Professor, Head of the
Department of Therapy, FAGE,
Samarkand State Medical Institute

Alieva Nigora Rustamovna
Doctor of Medical Sciences, Head of the
Department of Hospital Pediatrics
No. 1 with the basics of alternative
medicine, TashPMI

Ismailova Adolat Abduraximovna
doctor of Medical Sciences, Professor,
Head of the Laboratory of Fundamental
Immunology of the Institute of
Immunology of Human
Genomics of the Academy of Sciences
of the Republic of Uzbekistan

Kamalov Zaynitdin Sayfutdinovich
doctor of Medical Sciences, Professor,
Head of the Laboratory of
Immunogenetics of the Institute of
Immunology and Human Genomics
of the Academy of Sciences of the
Republic of Uzbekistan

Kayumov Ulugbek Karimovich
Doctor of Medical Sciences, Professor,
Head of the Department of Internal
Diseases and Telemedicine of the Center
for the development of professional
qualifications
of medical workers

Khusinova Shoira Akbarovna
PhD, Associate Professor, Head of the
Department of General Practice,
Family Medicine FAGE of the
Samarkand State Medical Institute

Shodikulova Gulandom Zikriyevna
Doctor of Medical Sciences, professor,
head of the Department of Internal
Diseases N 3 of Samarkand state medical
institute (Samarkand)
<https://orcid.org/0000-0003-2679-1296>

Doniyorova Farangisbonu Alisher kizi
Associate Professor, Department of
Neurology and Traditional Medicine,
Tashkent State Medical University, DSc.
<https://orcid.org/0009-0004-4140-4797>

Халиков Каххор Мирзаевич
кандидат медицинских наук, доцент
заведующий кафедрой биологической
химии Самаркандского
государственного медицинского
университета

Тулабаева Гавхар Миракбаровна
Заведующая кафедрой кардиологии,
Центр развития профессиональной
квалификации медицинских
работников, д.м.н., профессор

**Абдумаджидов Хамидулла
Амануллаевич**

Бухарский государственный
медицинский институт имени Абу
Али ибн Сино. Кафедра «Хирургические
болезни и реанимация». Доктор
медицинских наук, профессор.

Саидов Мақсуд Арифович

к.м.н., директор Самаркандского
областного отделения
Республиканского специализированного
научно-практического медицинского
центра кардиологии (г. Самарканд)

Срождинова Нигора Зайнутдиновна

д.м.н. Заведующая научно-
исследовательской лабораторией
кардиодиабета и метаболических
нарушений РСНПМЦК

Носирова Дилангиз Акбаровна

Ассистент кафедры внутренних
болезней и кардиологии №2
Самаркандского государственного
медицинского университета
(технический секретарь)

Эсанкулов Мухаммад Олимович

Ассистент кафедры внутренних
болезней и кардиологии №2
Самаркандского государственного
медицинского университета
(технический секретарь)

Xalikov Qaxxor Mirzayevich
Tibbiyot fanlari nomzodi, dotsent
Samarqand davlat tibbiyot universiteti
Biologik kimyo kafedrasini mudiri

Tulabayeva Gavxar Mirakbarovna
kardiologiya kafedrasini mudiri, tibbiyot
xodimlarining kasbiy malakasini rivojlantirish
markazi, tibbiyot fanlari doktori, professor

Abdumadjidov Xamidulla Amanullayevich

«Abu Ali ibn Sino nomidagi Buxoro davlat
tibbiyot oliygohi» Xirurgiya kasalliklari va
reanimatsiya kafedrasini professori, tibbiyot
fanlari doktori.

Saidov Maqsud Arifovich

tibbiyot fanlari nomzodi,
Respublika ixtisoslashgan kardiologiya
ilmiy amaliy tibbiyot markazi Samarqand
viloyat mintaqaviy filiali direktori
(Samarqand)

Srojidinova Nigora Zaynutdinovna

t.f.d. Kardiodiabet va metabolik buzilishlar
ilmiy tadqiqot laboratoriyasi mudiri

Nosirova Dilangiz Akbarovna

Samarqand davlat tibbiyot universiteti 2-son
ichki kasalliklar va kardiologiya kafedrasini
assistenti (texnik kotib)

Esankulov Muxammad Olimovich

Samarqand davlat tibbiyot universiteti 2-son
ichki kasalliklar va kardiologiya kafedrasini
assistenti (texnik kotib), PhD

Khalikov Kakhor Mirzayevich
Candidate of Medical Sciences,
Associate Professor, Head of the Department
of Biological Chemistry, Samarkand State
Medical University

Tulabayeva Gavxar Mirakbarovna

Head of the Department of Cardiology,
Development Center professional
qualification of medical workers,
MD, professor

**Abdumadjidov Khamidulla
Amanullayevich**

“Bukhara state medical institute named
after Abu Ali ibn Sino”. DSc, professor.

Saidov Maksud Arifovich

Candidate of Medical Sciences, Director
of the Samarkand Regional Department of
the Republican Specialized Scientific and
Practical Medical Center of Cardiology
(Samarkand)

Srojidinova Nigora Zaynutdinovna

DSc, Head of Kardiodiabetes and Metabolic
Disorders Laboratory

Dilangiz Akbarovna Nosirova,

Assistant of the Department of Internal
Diseases and Cardiology No. 2, Samarkand
State Medical University (Technical Secretary)

Esankulov Muhammad Olimovich,

Assistant of the Department of Internal
Diseases and Cardiology No. 2, Samarkand
State Medical University (Technical Secretary)

СИСТЕМНЫЕ ЗАБОЛЕВАНИЯ СОЕДИНИТЕЛЬНОЙ ТКАНИ: СОВРЕМЕННЫЕ ПОДХОДЫ

1.	M.Z. Axadova Revmatoid artrit va yurak ishemik kasalligi М.З. Ахадова Ревматоидный артрит и ишемическая болезнь сердца M.Z. Axadova Rheumatoid arthritis and heart ischemic disease.....	11
2.	И.А. Ахмедов, Г.З. Шодикүлова Оценка клинической и иммунологической эффективности применения генно-инженерных биологических препаратов с использованием инфузионной помпы при ревматических заболеваниях I.A. Akhmedov, G.Z. Shodikulova Evaluation of the clinical and immunological effectiveness of genetically engineered biological drugs administered via an infusion pump in rheumatic diseases I.A. Axmedov, G.Z. Shodikulova Revmatik kasalliklarda infuzion pompa yordamida gen-injener biologik dori vositalarini qo'llashning klinik va immunologik samaradorligini baholash.....	14
3.	З.Б. Бабамурадова, Н.Н. Шаваз Особенности течения антифосфолипидного синдрома у беременных женщин Z.B. Babamuradova, N.N. Shavazi Features of the course of antiphospholipid syndrome in pregnant women Z.B. Babamuradova, N.N. Shavazi Homilador ayollarda antifosfolipid sindromning kechish xususiyatlari.....	19
4.	Л.С. Батырбекова, С.А. Серикова, З.А. Базарбаева, О.В. Казимирова, А.Р. Бейсенаева, З.А. Кенжетаяева, Б.М. Телегенова, Б.Д. Жапаркул Роль искусственного интеллекта в современной медицине (обзор литературы) L.S. Batyrbekova, S.A. Serikova, Z.A. Bazarbayeva, O.V. Kazimirova, A.R. Beisenayeva, Z.A. Kenzhetayeva, B.M. Telegenova, B.D. Zhaparkul The role of artificial intelligence in modern medicine (literature review) L.S. Batyrbekova, S.A. Serikova, Z.A. Bazarbayeva, O.V. Kazimirova, A.R. Beysenayeva, Z.A. Kenzhetayeva, B.M. Telegenova, B.D. Japarkul Zamonaviy tibbiyotda sun'iy intellektning roli (adabiyotlar sharhi).....	22
5.	Д.Х.Бердиев; С.Х.Ярмухамедова Сравнительная оценка влияния фебуксостата и аллопуринола на показатели эндотелиальной дисфункции у пациентов с коморбидным течением подагры и артериальной гипертензии D.H. Berdiev; S.X. Yarmukhamedova Comparative evaluation of the effect of febusostat and allopurinol on endothelial dysfunction parameters in patients with comorbid gout and arterial hypertension D.H. Berdiyev; S.X. Yarmuxamedova Podagra va arterial gipertenziya komorbid kechgan bemorlarda febuxostat va allopurinolning endotelial disfunktsiya ko'rsatkichlariga ta'sirini qiyosiy baholash.....	26
6.	Вохидов Ж. Ж., Рўзманова Г.И. Псориатический артрит и сердечно-сосудистые заболевания: многогранные коморбидные состояния и интегрированный подход к лечению Vokhidov J.J., Ruzmanova G.I Cardiovascular disease in psoriatic arthritis: multidimensional comorbidities and an integrated treatment approach Vohidov J.J., Ro'zmanova G. I. Psoriatik artritda yurak-qon tomir kasalliklari: ko'p qirrali qo'shma kasalliklar va integratsiyalashgan davolash yondashuvi.....	31
7.	Г.Д. Клеблеева, У.А. Ташкенбаева, Г.З. Шодикүлова Особенности диагностики и лечения аллергических васкулитов (кожно-сосудистых) на фоне коморбидных состояний G.D. Klebleyeva, U.A. Tashkenbaeva, G.Z. Shodikulova Diagnosis and treatment of allergic vasculitis (cutaneous and vascular) associated with comorbid conditions G.D. Klebleeva, U.A. Tashkenbaeva, G.Z. Shodikulova Komorbid holatlar bilan bog'liq allergik vaskulit (teri va qon tomir) diagnostikasi va davolash.....	36
8.	Г.З. Мухитдинова Волчаночный нефрит: эпидемиология прогрессирования и современные стратегии доказательной терапии G.Z. Mukhitdinova Lupus nephritis: epidemiology of progression and modern evidence-based therapy strategies G.Z. Muxitdinova Volchanochniy nefrit: kasallik progressiyasining epidemiologiyasi va zamonaviy dalillarga asoslangan terapiya strategiyalari.....	41

9.	Д.А.Набиева, С.Б.Мамасиддикова, А.А.Мамасиддиқов, А.Т. Шаропова. Особенности течения беременности и факторы риска тромбоцитопении у пациенток с системной красной волчанкой D.A.Nabiyeva, S.B.Mamasiddikova, A.A. Mamasiddikov, A.T. Sharopova. Features of pregnancy course and risk factors for thrombocytopenia in patients with systemic lupus erythematosus D.A.Nabiyeva, S.B.Mamasiddiqova, A.A. Mamasiddiqov, A.T. Sharopova.. Tizimli qizil yuguruk bilan ogʻrigan bemorlarda homiladorlik kechishining xususiyatlari va trombositopeniya rivojlanish xavf omillari.....	47
10.	Б.У. Низомов, К.А. Исламова Роль активности системы комплемента в формировании системной красной волчанки B.U. Nizomov, K.A. Islamova The role of complement system activity in the development of systemic lupus erythematosus B.U. Nizomov, K.A. Islamova Komplement tizimi faolligining tizimli qizil yugurik shakllanishidagi oʻrni.....	51
11.	М.С. Равшанова, Х.И. Ибрагимов, Ш.Х. Зиядуллаев Клиническая эффективность комбинированной терапии биологическими и синтетическими БПВП при ревматоидном артрите M.S. Ravshanova, Kh.I. Ibragimov, Sh.X. Ziyadullayev Clinical effectiveness of biologic and synthetic DMARD combination therapy in rheumatoid arthritis M.S. Ravshanova, X.I. Ibragimov, Sh.X. Ziyadullayev Revmatik artritda biologik va sintetik DMARD'lar kombinatsiyali terapiyasining klinik samaradorligi.....	56
12.	М.С. Равшанова, М.А. Эшбеков, Х.И. Ибрагимов, Ш.Х. Зиядуллаев Современные иммунопатогенетические механизмы ревматоидного артрита M.S. Ravshanova, M.A. Eshbekov, Kh.I. Ibragimov, Sh.X. Ziyadullaev Modern immunopathogenetic mechanisms of rheumatoid arthritis M.S. Ravshanova, M.A. Eshbekov, X.I. Ibragimov, Sh.X. Ziyadullaev Revmatik artritning zamonaviy immunopatogenetik mexanizmlari.....	60
13.	Д.Р. Таиров, Д.Х. Бердиев Клинико-иммунологические и генетические особенности кардиоренальных поражений и метаболического синдрома при подагре и гиперурикемии D.R. Tairov, D.H. Berdiyev Clinical, immunological and genetic characteristics of cardiorenal lesions and metabolic syndrome in gout and hyperuricemia D.R. Tairov, D.H. Berdiyev Podagra va giperurikemiya holatida kardiorrenal zararlanishlar hamda metabolik sindromning klinik, immunologik va genetik xususiyatlari.....	67
14.	З.К. Таирова, Г.З. Шодиккулова Современные этиологические аспекты и стратификация факторов риска развития остеопороза Z.K. Tairova, G.Z. Shodikulova Modern etiological aspects and stratification of risk factors for osteoporosis development Z.K. Tairova, G.Z. Shodiqulova Osteoporoz rivojlanishining zamonaviy etiologik jihatlari va xavf omillarining stratifikatsiyasi.....	72
15.	М. М. Туркманов Современное состояние проблемы остеоартроза у пациентов с недифференцированной дисплазией соединительной ткани M. M. Turkmanov Differensiyalanmagan biriktiruvchi toʻqima displaziyasi boʻlgan bemorlarda osteoartroz muammosining zamonaviy holati M. M. Turkmanov Current state of the problem of osteoarthritis in patients with undifferentiated connective tissue dysplasia.....	78
16.	Хасанов О.Г., Хазратов Н.М Микробиота кишечника и ревматоидный артрит: обзор литературы Khasanov O.G., Khazratov N.M. Gut microbiota and rheumatoid arthritis: a literature review Xasanov O.G., Xazratov N.M Ichak mikrobiotasi va revmatoid artrit: adabiyotlar sharhi.....	82
17.	Хусанов М.У., Эргашова М.М. Системная красная волчанка: эпидемиология, патогенез, диагностика и современные подходы к лечению Khusanov M.U., Ergashova M.M. Systemic lupus erythematosus: epidemiology, pathogenesis, diagnosis and modern treatment approaches Xusanov M.U., Ergashova M.M. Tizimli qizil yuguriq: epidemiologiya, patogenez, tashxis va zamonaviy davolash yondashuvlari.....	88

18.	<p>G.Z. Shodikulova, Sh.N. Sadikova Revmatoid artritda osteoporoz rivojlanish xavfini kompleks kliniko-genetik va instrumental baholash: D vitamini metabolizmi, VDR polimorfizmlari va suyak mineral zichligi parametrlari Г.З. Шодикүлова, Ш.Н. Садикова Комплексная клиничко-генетическая и инструментальная оценка риска развития остеопороза при ревматоидном артрите: метаболизм витамина Д, полиморфизмы VDR и параметры минеральной плотности костей G.Z. Shodikulova, Sh.N. Sadikova Comprehensive clinical-genetic and instrumental assessment of the risk of osteoporosis in rheumatoid arthritis: metabolism of vitamin D, VDR polymorphism and parameters of bone mineral density.....</p>	92
19.	<p>Г.З. Шодикүлова, О.Ф. Шамсиев Клиничко-патогенетические аспекты развития остеопороза у женщины G.Z. Shodikulova, O.F. Shamsiev Clinical and pathogenetic aspects of osteoporosis development in women G.Z. Shodikulova, O.F. Shamsiyev Ayollarda osteoporoz rivojlanishining klinik-patogenetik jihatlari.....</p>	96
20.	<p>Мирзаев О.В., Нурмаматов Ж.Х. Распространенность и клиничко-генетические особенности дисплазии соединительной ткани у узбекского населения Mirzayev O.V., Nurmatov J.Kh. Prevalence and clinical - genetic features of connective tissue dysplasia in the uzbek population Mirzayev O.V., Nurmatov J.X. O'zbek populyatsiyasida biriktiruvchi to'qima displaziyasining tarqalishi va klinik-genetik xususiyatlari.....</p>	102



Равшанова М.С.

Самаркандский государственный медицинский университет
Самарканд, Узбекистан

Ибрагимов Х.И.

Самаркандский государственный медицинский университет
Самарканд, Узбекистан

Зиядуллаев Ш.Х.

Самаркандский государственный медицинский университет
Самарканд, Узбекистан

КЛИНИЧЕСКАЯ ЭФФЕКТИВНОСТЬ КОМБИНИРОВАННОЙ ТЕРАПИИ БИОЛОГИЧЕСКИМИ И СИНТЕТИЧЕСКИМИ БПВП ПРИ РЕВМАТОИДНОМ АРТРИТЕ

For citation: M.S. Ravshanova, Kh.I. Ibragimov, Sh.X. Ziyadullayev. CLINICAL EFFECTIVENESS OF BIOLOGIC AND SYNTHETIC DMARDS COMBINATION THERAPY IN RHEUMATOID ARTHRITIS. Journal of cardiorespiratory research. 2026, vol 7, issue 2/3.



<http://dx.doi.org/10.26739/2181-0974/2026/7/2/3/12>

АННОТАЦИЯ

Данное наблюдательное когортное исследование оценивало эффективность и безопасность комбинированной терапии ритуксимабом и метотрексатом у пациентов с ревматоидным артритом (РА), у которых отмечался недостаточный ответ на монотерапию метотрексатом. Пациенты были разделены на три группы.

Первичной конечной точкой было изменение индекса активности заболевания DAS28 (Disease Activity Score по 28 суставам) от исходного уровня до 6 месяцев. Вторичные конечные точки включали достижение критериев ответа Американской коллегии ревматологов (ACR) 20, 50 и 70, изменения показателей индекса инвалидизации HAQ-DI (Health Assessment Questionnaire-Disability Index), а также рентгенологическое прогрессирование, оцененное с использованием модифицированного индекса Sharp/van der Heijde (mTSS).

Результаты показали, что комбинация ритуксимаба и метотрексата значительно превосходила монотерапию метотрексатом в достижении клинически значимых ответов (ACR20, ACR50 и ACR70) в течение девяти месяцев лечения. Группа IB, получавшая более высокую дозу метотрексата, продемонстрировала несколько более высокие показатели клинического улучшения по сравнению с группой IA, однако различия не были статистически значимыми. Через девять месяцев 88,9% пациентов в группе IB достигли ответа ACR20 по сравнению с 74,2% в группе IA и 46% в группе сравнения. Аналогичные тенденции наблюдались для ответов ACR50 и ACR70. Исследование показывает, что комбинация ритуксимаба и метотрексата клинически превосходит монотерапию метотрексатом при лечении ревматоидного артрита, при этом более высокая доза метотрексата может быть связана с лучшими исходами.

Ключевые слова: ревматоидный артрит, ритуксимаб, метотрексат, наблюдательное исследование, активность заболевания, ACR20, ACR50, ACR70.

Ravshanova M.S.

Samarkand State Medical University
Samarkand, Uzbekistan

Ibragimov Kh.I.

Samarkand State Medical University
Samarkand, Uzbekistan

Ziyadullayev Sh.X.

Samarkand State Medical University
Samarkand, Uzbekistan

CLINICAL EFFECTIVENESS OF BIOLOGIC AND SYNTHETIC DMARDS COMBINATION THERAPY IN RHEUMATOID ARTHRITIS

ANNOTATION

This observational cohort study assessed the efficacy and safety of rituximab and methotrexate combination therapy in patients with rheumatoid arthritis (RA) who had an inadequate response to methotrexate monotherapy. Patients were divided into three groups. The primary outcome was the change in the Disease Activity Score based on 28 joints (DAS28) from baseline to 6 months. Secondary outcomes included the American College of Rheumatology (ACR) 20, 50, and 70 responses, changes in the Health Assessment Questionnaire-Disability Index (HAQ-DI) scores, and radiographic progression assessed using the modified Sharp/van der Heijde score (mTSS). Results showed that the combination of rituximab and methotrexate was significantly superior to methotrexate monotherapy in achieving clinically significant responses (ACR20, ACR50, and

ACR70) over nine months of treatment. Group IB, receiving a higher dose of methotrexate, exhibited slightly better clinical improvement rates than Group IA, although the difference was not statistically significant. By nine months, 88.9% of patients in Group IB achieved an ACR20 response, compared to 74.2% in Group IA and 46% in the comparison group. Similar trends were observed for ACR50 and ACR70 responses. The study suggests that the combination of rituximab and methotrexate is clinically superior to methotrexate monotherapy in the treatment of RA, with a higher methotrexate dose potentially leading to better outcomes.

Keywords: Rheumatoid arthritis, rituximab, methotrexate, observational study, disease activity, ACR20, ACR50, ACR70.

Ravshanova M.S.

Samarqand davlat tibbiyot universiteti

Samarqand, O'zbekiston

Ibragimov X.I.

Samarqand davlat tibbiyot universiteti

Samarqand, O'zbekiston

Ziyadullayev Sh.X.

Samarqand Davlat Tibbiyot Universiteti

Samarqand, O'zbekiston

РЕВМАТОИД АРТРИТДА BIOLOGIK VA SINTETIK DMARD'LAR KOMBINATSIYALI TERAPIYASINING KLINIK SAMARADORLIGI

ANNOTATSIYA

Ushbu kuzatuvli kohorta tadqiqoti revmatoid artrit (RA) bilan og'riqan, metotreksat monoterapiyasiga yetarlicha javob bermagan bemorlarda rituksimab va metotreksat kombinatsiyali terapiyasining samaradorligi va xavfsizligini baholadi. Bemorlar uch guruhga bo'lingan. Birinchi darajali yakuniy ko'rsatkich 6 oy davomida 28 bo'g'im bo'yicha kasallik faoliyati indeksi (DAS28 – Disease Activity Score) o'zgarishi bo'ldi. Ikkinchi darajali yakuniy ko'rsatkichlar qatoriga Amerika revmatologlar kollegiyasi (ACR) 20, 50 va 70 javob darajalari, sog'liqni baholash so'rovi bo'yicha nogironlik indeksi (HAQ-DI – Health Assessment Questionnaire-Disability Index) o'zgarishlari, shuningdek, modifikatsiyalangan Sharp/van der Heijde indeksi (mTSS) yordamida rentgenologik progressiya kiradi. Natijalar shuni ko'rsatdiki, rituksimab va metotreksat kombinatsiyasi metotreksat monoterapiyasiga nisbatan klinik jihatdan sezilarli javoblarni (ACR20, ACR50 va ACR70) olishda sezilarli darajada ustun bo'ldi. IB guruhi, yuqori dozalangan metotreksat olgan bemorlar, IA guruhi bilan solishtirganda biroz yaxshiroq klinik yaxshilanish ko'rsatkichlarini namoyish etdi, ammo farq statistik jihatdan sezilarli emas edi. 9 oy davomida IB guruhining 88,9% bemorlari ACR20 javobini oldi, IA guruhida bu ko'rsatkich 74,2% va taqqoslash guruhida 46% edi. ACR50 va ACR70 javoblarida shunga o'xshash tendensiyalar kuzatildi. Tadqiqot shuni ko'rsatdiki, rituksimab va metotreksat kombinatsiyasi revmatoid artritni davolashda metotreksat monoterapiyasiga nisbatan klinik jihatdan ustun bo'lib, metotreksatning yuqori dozalari yaxshiroq natijalarga olib kelishi mumkin.

Kalit so'zlar: revmatoid artrit, rituksimab, metotreksat, kuzatuvli tadqiqot, kasallik faoliyati, ACR20, ACR50, ACR70.

Introduction

Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease characterized by inflammation of the synovial joints, leading to progressive joint destruction, pain, and disability. The etiology of RA is complex and multifactorial, involving genetic, environmental, and immunological factors that contribute to the pathogenesis of the disease. The clinical manifestations of RA are diverse, ranging from mild joint stiffness to severe joint damage and systemic complications, impacting the quality of life of affected individuals [1–4,16].

The management of RA has evolved significantly over the past few decades, with the advent of disease-modifying antirheumatic drugs (DMARDs) and biologic agents that target specific components of the immune system. Methotrexate is a conventional DMARD that has been a cornerstone in the treatment of RA due to its efficacy in controlling disease activity and slowing disease progression. However, not all patients respond adequately to methotrexate monotherapy, necessitating the use of combination therapy or alternative agents [1,4,6,9].

Biologic agents, such as monoclonal antibodies, have revolutionized the treatment landscape of RA. Rituximab, a fully human monoclonal antibody that inhibits CD20 on B lymphocytes, has demonstrated significant efficacy in reducing the signs and symptoms of RA, inhibiting the progression of joint damage, and improving physical function when used alone or in combination with methotrexate [5,6].

Despite the availability of effective therapies, the optimal treatment strategy for individual patients remains a challenge. The heterogeneity of the disease and the variability in patient response to treatment underscore the need for personalized approaches and the exploration of different treatment regimens. In this context, the present study aims to compare the efficacy and safety of different combinations of rituximab and methotrexate in patients with RA who have an inadequate response to methotrexate monotherapy [7,8, 12-15].

This study is designed to provide insights into the comparative effectiveness of these treatment regimens, which may inform clinical decision-making and contribute to the optimization of therapeutic

strategies for patients with RA. The results section of this article presents the findings of this investigation, including the demographic and baseline clinical characteristics of the patients, the impact of the treatment regimens on disease activity, and the safety profile of the combinations.

Materials and methods

This observational cohort study was conducted to compare the efficacy and safety of different combinations of rituximab and methotrexate in patients with RA who had an inadequate response to methotrexate monotherapy. Adult patients (aged ≥ 18 years) diagnosed with RA according to the 2010 American College of Rheumatology/European League Against Rheumatism criteria, with a disease duration of at least 6 months, were included in the study. Eligible participants had active disease, defined as having at least 6 swollen joints and 6 tender joints, along with either an ESR > 28 mm/hour or a CRP level > 1.0 mg/dL.

Participants were categorized into three exposure groups based on their treatment regimen:

Group IA: Rituximab 1000 mg IV at day 1 and 15 + methotrexate 7.5 mg orally once weekly

Group IB: Rituximab 1000 mg IV at day 1 and 15 + methotrexate 15 mg orally once weekly

Comparison Group: Methotrexate 15 mg orally once weekly

The primary outcome was the change in the DAS28 from baseline to 6 months. Secondary outcomes included the ACR20, ACR50, and ACR70 responses, changes in the HAQ-DI scores, and radiographic progression assessed using the modified Sharp/van der Heijde score (mTSS).

Data on demographic characteristics, clinical parameters, treatment regimens, and outcomes were collected from medical records and patient interviews. Descriptive statistics were used to summarize baseline characteristics. Comparative analyses between the exposure groups were performed using chi-square tests for categorical variables and ANOVA or Kruskal-Wallis tests for continuous variables, as appropriate. Multivariable regression analyses were conducted to adjust

for potential confounders and to estimate the adjusted effect of the treatment regimens on the outcomes.

The study protocol was approved by the institutional review board or ethics committee at each participating center, and the study was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines. Written informed consent was obtained from all participants before enrollment in the study.

Results

Demographic and baseline clinical characteristics of the patients reflected a population with RA and were comparable among the 3 treatment groups. We divided patients into three groups. Group - IA consisted of patients who received a combinations of rituximab 1000mg at days 1 and 15 + methotrexate 7.5mg weekly, IB- those who received a combinations of rituximab 1000mg + methotrexate 15mg and the comparison group received only methotrexate 15mg once weekly. The mean age of patients were 43.4±15.7 years in group IA, 41.8±14.7 years in group IB and 42.9±6.2 years of the patients following MTX monotherapy in comparison group. We found no statistically significant difference between the comparison groups in terms of mean age of

participants (p>0.05). Majority of the patients were females in all three groups with no difference in the female male ratio between the groups (67.7%, 66.7% and 69.0% respectively). In each treatment group, the mean duration of RA at baseline was 6.7, 7.2 and 6.9 years respectively. Majority of patients had disease duration of between 3-7 years. Of notes, 12 (38.7%) patients in IA group, 11 (40.7%) patients in IB group and 44 (44.0%) patients taking methotrexate monotherapy had disease duration of between 3 to 7 years. Moreover, over 60% of the study patients in all groups had RA for over 5 years. We found no statistically significant difference between the comparison groups in the disease duration (p>0.05). Similar percentages of patients in each treatment group had previously received treatment with a DMARD (other than MTX). Among all patients who previously received DMARDs, 41% had received leflunomide and 39% had received sulfasalazine. Approximately one-third of patients in each treatment group were taking corticosteroids at baseline (38.7%, 37.0% and 37.0% respectively). The mean corticosteroid dosage (prednisone equivalent) was 12.7 mg/day in the IA treatment arm, 13.1 mg/day in the IB treatment arm, and 14.8 mg/day in the comparison group (table 1).

Table 1. Characteristics of patients according to treatment group

	Group IA (n = 31)	Group IB (n = 27)	Comparison group (n = 100)
Age, years (m±sd)	43.4±15.7	41.8±14.7	42.9±6.2
Male n(%)	10(32.3%)	9 (33.3%)	31 (31.0%)
Female n(%)	21 (67.7%)	18 (66.7%)	69 (69.0%)
Disease duration (years)	6.7±1.9	7.2±1.2	6.9±2.1
Disease duration<1 years	9 (29.0%)	7 (25.9%)	30 (30.0%)
Disease duration 1-3 years	12 (38.7%)	11 (40.7%)	44 (44.0%)
Disease duration >3 years	10 (32.3%)	9 (33.3%)	28 (28.0%)
Taking corticosteroids n (%)	12 (38.7)	10 (37.0%)	37 (37.0%)
Tender joint count (0-68)	35.8±14.8	36.2±15.6	37.3±1.1
Swollen joint count (0-66)	27.2±13.6	29.2±13.1	30.5±11.4
C-reactive protein (mg/dl)	3.9±4.2	4.1±3.9	4.0±4.0
ESR (mm/h)	29.5± 8.2	28.5± 8.9	27.2± 5.4
Anti-CCP positive n (%)	30 (96.7%)	27 (100%)	100 (100.0%)
RF positive n (%)	28 (90.3%)	24 (88.9%)	81 (81.0%)

Note: ESR- Erythrocyte Sedimentation Rate; MTX-methotrexate. RF-rheumatoid factor. CCP- cyclic citrullinated peptide, statistical significance *-p<0.05

In terms of joint involvement, both tender and swollen joint counts exhibited similar values across Group IA (35.8±14.8 and 27.2±13.6, respectively), Group IB (36.2±15.6 and 29.2±13.1, respectively), and the comparison group (37.3±1.1 and 30.5±11.4, respectively). These figures imply a consistency in the severity of joint tenderness and swelling at the baseline within this patient cohorts. Similarly, the levels of inflammatory markers, CRP (Group IA: 3.9±4.2, Group IB: 4.1±3.9, Comparison group: 4.0±4.0) and ESR (Group IA: 29.5±8.2, Group IB: 28.5±8.9, Comparison group: 27.2±5.4), did not display significant variations, indicating uniform disease activity among the groups at the baseline.

Furthermore, the prevalence of anti-CCP positivity was notably high in all groups, with percentages of 96.7% in Group IA, 100% in Group IB, and 100.0% in the Comparison group. Similarly, RF

positivity was prevalent, with percentages of 90.3% in Group IA, 88.9% in Group IB, and 81.0% in the Comparison group. These numbers underscore a consistent immunological profile among patients with RA at the commencement of the study. The lack of significant differences in the percentages of positive patients emphasizes the uniformity of autoimmune characteristics in the studied populations.

The presented baseline characteristics elucidate a remarkable homogeneity among patients with rheumatoid arthritis in terms of joint involvement, inflammatory markers, and autoimmune markers. These actual numerical findings provide a concrete understanding of the initial disease presentation and lay the groundwork for further exploration of treatment responses and disease progression in these distinct patient groups (table 2).

Table 2. Characteristics of disease activity and disability indexes in patients with RA

	Group IA (n = 31)	Group IB (n = 27)	Comparison group (n = 100)
HAQ - disability index	1.1±0.42	1.0±0.35	1.1±0.52
VAS score – physician (100-mm)	39.1±9.6	41.2±10.2	42.1±7.3
VAS score – patient (100-mm)	36.2±10.1	37.8±11.3	38.0±8.0
Patient’s assessment of pain	32.5 ±10.3	34.6±11.6	29.6±10.3
DAS28	6.3±0.9	6.4±0.9	6.3±0.9

Note: HAQ = Health Assessment Questionnaire; VAS = visual analog scale; DAS28 = 28-joint Disease Activity Score; Statistical significance *-p<0.05

The mean HAQ disability index was 1.1 ± 0.42 in group IA, 1.0 ± 0.35 in group IB and 1.1 ± 0.52 in the comparison group among those who received only methotrexate. There were not any statistically significant baseline differences among treatment groups in the HAQ disability score ($p > 0.05$). The mean VAS score assessed by physician's global assessment of disease activity did not show statistically significant baseline differences among the comparing groups with VAS score of 39.1 ± 9.6 , 41.2 ± 10.2 and 42.1 ± 7.3 respectively ($p > 0.05$). Similarly, the analysis of mean VAS score assessed by patient's global assessment of disease activity did not show significant baseline differences among the comparing groups ($p > 0.05$).

Table 3.3 delineates the baseline radiographic findings in patients with rheumatoid arthritis (RA) across three distinct groups. In terms of the TSS score, the numeric values indicate that group IA has a mean score of 2.2 ± 0.8 , group IB has 2.3 ± 0.8 , and the comparison group has 2.4 ± 0.7 . The associated p-values ($p_1 > 0.05$, $p_2 > 0.05$) suggest that there

were low to moderate level of joint damages across groups and are no statistically significant differences in the overall joint damage, as measured by the TSS scale between the groups.

Further examination of the erosion score reveals similar trends. Group IA demonstrates an erosion score of 1.1 ± 0.7 , group IB has 1.0 ± 0.5 , and the comparison group has 1.2 ± 0.7 . The p-values indicate no significant distinctions in bone damage among the groups.

Similarly, the joint space narrowing score demonstrates comparable values across the groups. Group IA has a score of 1.2 ± 0.8 , group IB has 1.3 ± 0.8 , and the comparison group has 1.2 ± 0.6 , with p-values denoting no statistically significant differences in cartilage loss levels.

The baseline radiographic findings, elucidated by actual numerical values and supported by p-values, portray a consistency in joint damage, bone erosion, and cartilage loss among patients with RA in the studied groups (table 3).

Table 3. Baseline radiographic findings in patients with rheumatoid arthritis

	Group IA (n = 31)	Group IB (n = 27)	Comparison group (n = 100)
mTSS score	2.2 ± 0.8	2.3 ± 0.8	2.4 ± 0.7
Erosion score	1.1 ± 0.7	1.0 ± 0.5	1.2 ± 0.7
Joint space narrowing score	1.2 ± 0.8	1.3 ± 0.8	1.2 ± 0.6

Note: TSS = total Sharp score; Statistical significance *- $p < 0.05$

The table 4 represents the rate of clinically significant response to treatment defined as ACR20, ACR50 and ACR70 based on criteria given by American College of Rheumatology among three different treatment groups. The data shows that the combination of rituximab and

methotrexate was significantly superior to the methotrexate monotherapy over the period of 9 months of treatment in clinically significant response rate defined as 20%, 50% and 70% improvement from baseline.

Table 4. Baseline characteristics of immunological indexes in patients with rheumatoid arthritis


	Group IA (n = 31)	Group IB (n = 27)	Comparison group (n = 100)
ACR20	23(74.2%)*	24(88.9%)*	46(46.0%)
ACR50	19 (61.3%)*	21(77.8%)*	39(39.0%)
ACR70	17(54.8%)*	18(66.7%)*	33(33.0%)

Note: *- $p < 0.05$

The improvement rates in group IA was slightly lower than the rates among the IB group patients which suggests that combinations of rituximab with 15mg of methotrexate may lead to better clinical improvement compared to the combination with 7.5mg of methotrexate, however, this trend was not statistically significant ($p > 0.05$). By 9 months of treatment 88.9% of patients in IB group reached clinically significant 20% improvement compared to 74.2% patients in IA and only 46% in comparison group ($p_1 < 0.05$, $p_2 < 0.05$). Similar response rates trend was observed when assessed for clinically important 50% and 70% improvements in patients from baseline. As per results, by


month 9, 66.7% of patients in group IB reached 70% improvement clinical, functional and laboratory findings compared to 54.8% patients in IA groups and only 33.0% of those receiving methotrexate monotherapy. The obtained results suggests that, rituximab and methotrexate combinations is clinically significantly superior compared to methotrexate monotherapy in treatment of rheumatoid arthritis. The combination of rituximab with 15 mg methotrexate tends to be superior to the combination with 7.5mg of methotrexate, however, statistically significant difference between combinations groups was not observed.

Picture 1. The longitudinal comparison of response rate by ACR20 criteria across all treatment groups.



The graph 1 presents a longitudinal comparison of the percentage of patients achieving a 20% improvement in symptoms, as defined by ACR20 criteria, over a period of nine months. From baseline to the 9-month mark, there is a notable increase in the percentage of patients achieving ACR20 across all groups. Group IA shows a consistent upward trajectory, starting at 22.0% at the first month and reaching 74.2% by the ninth month. Group IB, which received a higher dose of methotrexate in combination with rituximab, starts at a similar level of improvement in the first month (26.0%) but shows a faster rate of increase, achieving the highest percentage of improvement across all groups by the end of the study period (88.9% at month 9). This suggests


a dose-response effect, with higher doses of methotrexate potentially leading to better outcomes when combined with rituximab ($p < 0.05$). The comparison group, treated with methotrexate monotherapy, demonstrates a more gradual and less pronounced improvement ending at 46.0%. While there is improvement, it is considerably less than that seen in the combination therapy groups. Statistically, the graph indicates that both combination therapy groups (IA and IB) are significantly superior to the methotrexate monotherapy group, as evidenced by the final percentages and the apparent gaps between the curves. Specifically, Group IB's final ACR20 improvement rate is nearly twice that of the comparison group, which is clinically significant.



Picture 2. The longitudinal comparison of response rate by ACR20 criteria across all treatment groups

The graph 2 illustrates the progression of the percentage of patients achieving a 70% improvement in rheumatoid arthritis symptoms over a nine-month treatment period, as defined by ACR70 criteria. This higher threshold of improvement is indicative of a more substantial amelioration of symptoms. Over the nine months, group IA experiences a gradual increase in patient response, starting from 13.0% and reaching 54.8% by the ninth month. The upward trend is consistent, with occasional plateaus, reflecting a continuous yet variable response to the treatment. Group IB, on the other hand, demonstrates a more rapid

initial increase, which suggests an early onset of significant improvement with the higher dose of methotrexate. After the initial surge, the increase continues at a steadier pace, eventually reaching 66.7% by month nine. This group consistently outperforms Group IA, indicating a dose-related response, where a higher methotrexate dose with rituximab may be more effective. The comparison group, which received only methotrexate monotherapy, exhibits the most modest improvement throughout the study period with a final ACR70 response rate of 33.0% at nine months.




Picture 3. The dynamics of tender joints count in patients with rheumatoid arthritis across all treatment groups.

The graph 3 provides a detailed depiction of the changes in the number of tender joints among patients with rheumatoid arthritis over a nine-month period, segmented by combinations treatment groups IA,

IB, and the comparison group. Over the course of the treatment, group IA showed a gradual decline in the mean number of tender joints, reaching 9.2 by the end of the ninth month. In comparison, group IB,

treated with rituximab in combination with a higher dose of methotrexate, exhibits a more pronounced decline in the number of tender joints. Starting from a similar baseline, the count drops sharply

within the first month and continues to decline, ending at 4.2 tender joints by the ninth month.



Picture 4. The dynamics of swollen joints count in patients with rheumatoid arthritis across all treatment groups.

This trend not only demonstrates the effectiveness of the treatment but also suggests that a higher dose of methotrexate may have a more potent effect on reducing joint tenderness when used alongside rituximab. The comparison group, also showed a reduction in tender joints from the baseline. However, the decline is less steep compared to the combination therapy groups. By the ninth month, the comparison group's mean number of tender joints stands at 16.7, which, while indicative of improvement, highlights a less robust response to monotherapy versus combination therapy.

The data suggests that while all treatments result in improvements in tender joints, the combination of rituximab with methotrexate is more effective, and the efficacy increases with the methotrexate dosage. The graph effectively visualizes the superiority of combination therapy over monotherapy in the management of tender joints in rheumatoid arthritis patients. It underscores the importance of considering both the type and dosage of medication when treating this disease to achieve optimal patient outcomes.

The graph 4.4 depicts the change in the number of swollen joints in patients with rheumatoid arthritis over a nine-month treatment period, segmented by treatment groups IA, IB, and the comparison group. Group IA, receiving a combination of rituximab 40mg and methotrexate 7.5mg, demonstrates a steady decrease in swollen joint count from 27.9 to 8.6. This reduction suggests that the treatment is effective in reducing joint swelling, a key symptom and marker of inflammation in rheumatoid arthritis. Group IB, which was administered rituximab 40mg in combination with a higher dose of methotrexate at 15mg, shows a more accelerated reduction in swollen joint count, starting at 29.2 and reaching 4.3 by the end of the nine months. The sharper decline relative to Group IA suggests that the increased dose of methotrexate may enhance the efficacy of the treatment in reducing swelling in the joints. The comparison group also exhibited a decline in the number of swollen joints, but it was less pronounced, ending at 14.8. Although there is an improvement, the graph highlights that the combination

therapy groups, particularly Group IB, are more effective in reducing the swollen joint count compared to monotherapy.

The data presented convey the overall effectiveness of the treatments in managing swollen joints, with the steepest decline in Group IB indicating the highest efficacy. This visual representation underscores the benefit of combination therapies, especially with higher methotrexate dosages, in treating the inflammatory symptoms of rheumatoid arthritis.

Conclusions

This observational cohort study demonstrated the superior efficacy of combination therapy with rituximab and methotrexate compared to methotrexate monotherapy in patients with rheumatoid arthritis (RA) who had an inadequate response to methotrexate alone. Over nine months of treatment, patients receiving combination therapy showed significantly higher rates of clinically meaningful improvements in disease activity, as measured by ACR20, ACR50, and ACR70 criteria. Specifically, the combination of rituximab with a higher dose of methotrexate (15 mg weekly) appeared to provide slightly better outcomes than the combination with a lower dose (7.5 mg weekly), although the difference was not statistically significant.

The study also highlighted the importance of considering both the type and dosage of medications in the management of RA to achieve optimal patient outcomes. The consistent reduction in tender and swollen joint counts further supports the effectiveness of combination therapy in controlling disease symptoms and reducing inflammation.

In summary, the findings of this study contribute to the growing body of evidence supporting the use of combination therapy with biologic agents and methotrexate in the treatment of RA. They underscore the need for personalized treatment strategies that consider the individual patient's response to therapy and disease severity. Future research should focus on long-term outcomes and the identification of predictors of response to optimize the management of RA and improve the quality of life for patients living with this chronic condition.

Список литературы / References/ Iqtiboslar:

1. Akram M. S. [и др.]. Challenges for biosimilars: focus on rheumatoid arthritis // *Critical Reviews in Biotechnology*. 2021. № 1 (41). С. 121–153.
2. Aletaha D., Smolen J. S. Diagnosis and management of rheumatoid arthritis: a review // *Jama*. 2018. № 13 (320). С. 1360–1372.
3. Anderson K. O. [и др.]. Rheumatoid arthritis: review of psychological factors related to etiology, effects, and treatment. // *Psychological bulletin*. 1985. № 2 (98). С. 358.
4. Bang L. M., Keating G. M. Rituximab: A Review of its Use in Rheumatoid Arthritis // *BioDrugs*. 2004. № 2 (18). С. 121–139.
5. Bartelds G. M. [и др.]. Clinical response to rituximab: relationship to anti-rituximab antibodies and serum rituximab concentrations in rheumatoid arthritis // *Annals of the rheumatic diseases*. 2007. № 7 (66). С. 921–926.

6. Buchs N. d [и др.]. IL-1B and IL-1Ra gene polymorphisms and disease severity in rheumatoid arthritis: interaction with their plasma levels // *Genes & immunity*. 2001. № 4 (2). С. 222–228.
7. Firestein G. S. Evolving concepts of rheumatoid arthritis // *Nature*. 2003. № 6937 (423). С. 356–361.
8. Kim G. W. [и др.]. IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future // *Archives of pharmacal research*. 2015. (38). С. 575–584.
9. Narazaki M., Tanaka T., Kishimoto T. The role and therapeutic targeting of IL-6 in rheumatoid arthritis // *Expert Review of Clinical Immunology*. 2017. № 6 (13). С. 535–551.
10. Ogata A. [и др.]. IL-6 inhibitor for the treatment of rheumatoid arthritis: a comprehensive review // *Modern rheumatology*. 2019. № 2 (29). С. 258–267.
11. Pickens S. R. [и др.]. IL-17 contributes to angiogenesis in rheumatoid arthritis // *The Journal of Immunology*. 2010. № 6 (184). С. 3233–3241.
12. Radu A.-F., Bungau S. G. Management of rheumatoid arthritis: an overview // *Cells*. 2021. № 11 (10). С. 2857.
13. Rajaei E. [и др.]. Evaluating the relationship between serum level of interleukin-6 and rheumatoid arthritis severity and disease activity // *Current rheumatology reviews*. 2020. № 3 (16). С. 249–255.
14. Smolen J. S., Aletaha D. Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges // *Nature Reviews Rheumatology*. 2015. № 5 (11). С. 276–289.
15. Van Den Berg W. B., Miossec P. IL-17 as a future therapeutic target for rheumatoid arthritis // *Nature Reviews Rheumatology*. 2009. № 10 (5). С. 549–553.
16. Ziolkowska M. [и др.]. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism // *The Journal of Immunology*. 2000. № 5 (164). С. 2832–2838.